(ÇÏÀ̺긮µå)2022³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦20Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸ : 2022-05-20±³À°ÀÏÀÚ : 2022-05-20
±³À°Àå¼Ò : ¼¿ï·Ôµ¥È£ÅÚ(¼Ò°øµ¿)
±³À°ÁÖÁ¦ :
(ÇÏÀ̺긮µå)2022³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦20Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : ´ëÇÑÁ¾¾ç³»°úÇÐȸ
¿¬¶ôó : 02-735-2857
À̸ÞÀÏ :
meetings@ksmo.or.kr ±³À°Á¾·ù : ³»°ú¾à¸®ÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç, ÀÇ·áÁ¤Ã¥
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 7 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 70,000¿ø
ºñ°í »çÀüµî·Ï- ȸ¿ø : 40,000, ÁØȸ¿ø : 30,000, 65¼¼ ÀÌ»ó : ¹«·á -ºñȸ¿ø ±³¼ö, Àü¹®ÀÇ ¹Ú»ç±Þ ¿¬±¸¿ø : 50,000ÀüÀÓÀÇ, Àü°øÀÇ, °£È£»ç, ¾à»ç, ±ºÀÇ°ü, Çлý : 30,000ÇöÀåµî·Ï- ȸ¿ø : 60,000, ÁØȸ¿ø :50,000, 65¼¼ ÀÌ»ó : ¹«·á - ºñȸ¿ø±³¼ö, Àü¹®ÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø : 70,000ÀüÀÓÀÇ,Àü°øÀÇ, °£È£»ç, ¾à»ç, ±ºÀÇ°ü, Çлý : 50,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 09:00~09:40 Cost and value in cancer care Leonard Saltz(MSKCC)
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 09:40~10:00 One step back to move forward for KSMO ±èÅ¿ø(¼¿ï¾Æ»êº´¿ø)
±âŸ 05-20 Crystal Ballroom A (2F) 10:00~10:10 KSMO ¹Ì¼Ç/ºñÀü/Çٽɰ¡Ä¡ ¼±Æ÷½Ä ()
ÈÞ½Ä 05-20 Crystal Ballroom A (2F) 10:10~10:20 Break ()
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 10:20~10:35 Progress in precision oncology : KPMNG report ±èÅ¿ë(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 10:35~10:55 Challenges to harmonize Molecular Tumor Board decision – case sharing from KOSMOS study À̼¼ÈÆ(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 10:55~11:10 Implementing NGS and MTB guideline in clinical practice À±½Å±³(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 11:10~11:30 Lessons learned from Precision oncology clinical trials and suggestions for the future studies ÃÖÀ±Áö(°í´ë¾È¾Ïº´¿ø)
Åä·Ð 05-20 Crystal Ballroom A (2F) 11:30~11:40 Discussion ()
ÈÞ½Ä 05-20 Crystal Ballroom A (2F) 11:40~11:50 Break ()
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 11:50~12:30 ±è³ë°æ»ó ½Ã»ó ¹× °¿¬ ±è¿È«(°í´ë¾È¾Ïº´¿ø)
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 12:30~13:10 Rozlytrek: Leading a new era in Personalized Healthcare Á¶º´Ã¶(¿¬¼¼¾Ïº´¿ø)
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 13:10~13:25 Á¾¾ç³»°ú Àǻ簡 ¾Ë¾Æ¾ß ÇÒ ¾Ï ´ÙÇÐÁ¦ Á¦µµ ȲÀαÔ(Á߾Ӵ뺴¿ø)
Åä·Ð 05-20 Crystal Ballroom A (2F) 13:25~13:35 Discussion ()
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 13:35~13:50 Á¾¾ç³»°ú Àǻ簡 ¾Ë¾Æ¾ß ÇÒ ÀûÁ¤¼º Æò°¡ Á¦µµ °íÀ±È£(ÀºÆò¼º¸ðº´¿ø)
Åä·Ð 05-20 Crystal Ballroom A (2F) 13:50~14:00 Discussion ()
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 14:00~14:15 Á¾¾ç³»°ú Àǻ簡 ¾Ë¾Æ¾ß ÇÒ ÁöºÒÁ¦µµ Á¤ÁÖ¿µ(ÇѸ²´ëµ¿Åº¼º½Éº´¿ø)
Åä·Ð 05-20 Crystal Ballroom A (2F) 14:15~14:25 Discussion ()
Åä·Ð 05-20 Crystal Ballroom A (2F) 14:25~14:30 ÁÂÀå Á¤¸® ÅäÀÇ ()
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 14:30~14:40 2021³â º¸ÇèÁ¤Ã¥¿¬±¸ºñ»ó ¿¬±¸ ¹ßÇ¥ ¿ø¿µ¿õ(ÇѾç´ë±¸¸®º´¿ø)
ÈÞ½Ä 05-20 Crystal Ballroom A (2F) 14:40~14:50 Break ()
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 14:50~15:10 Identification of Resistance Mechanisms: Immune Checkpoint Therapy ¹ÚÁöÇö(°Ç±¹´ëº´¿ø)
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 15:10~15:30 Single cell genomics approach to identify immune determinants for PD-1 inhibitors ±èÇý·Ã(¿¬¼¼¾Ïº´¿ø)
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 15:30~15:50 T cell Exhaustion and Relevance for Immunotherapy of Cancer: ¹Ú¼öÇü(KAIST)
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 15:50~16:10 The Evolving Landscape of Immunotherapy ÀÌ´ëÈ£(¼¿ï¾Æ»êº´¿ø)
ÈÞ½Ä 05-20 Crystal Ballroom A (2F) 16:10~16:20 Break ()
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 16:20~17:00 Circulating tumor DNA to direct therapy for cancer Nicholas turner(The Institute of Cancer Research)
±âŸ 05-20 Crystal Ballroom A (2F) 17:00~17:30 Á¤±âÃÑȸ & Awards ()